


Case fatality due to cryptococcal meningitis in a retrospective cohort in Kenya

Kendi C¹, Penner J^{1,2}, Koech J¹, Nyonda M¹, Bukusi EA¹, Cohen CR^{1,3}, Muttai H⁴, Meyer AC^{1,3}



- 1. Family AIDS Care and Education Services (FACES), Research Care and Training Program, Center for Microbiology Research, Kenya Medical Research Institute
- 2. Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada
- 3. Department of Obstetrics, Gynaecology and Reproductive Sciences, University of California, San Francisco, California, USA
- 4. Global AIDS Program, US Centers for Disease Control and Prevention

Introduction

- Cryptococcal meningitis (CM) usually occurs in patients with a CD4<100</p>
- CM is the 2nd leading cause of death in African cohorts (1,2)
- CM has a case fatality rate of up to 81-100% in inpatient cohorts in sub-Saharan Africa (3,4) in contrast to a case fatality of 9% in the developed countries (5)

Objectives

- To determine case fatality due to cryptococcal meningitis among HIV infected individuals receiving out-patient HIV care and treatment in Kenya
- To determine key predictors of case fatality due to cryptococcal meningitis among HIV infected individuals


Methods

Study Site:

- Family Aids Care and Education Services (FACES)
- PEPFAR funded family-centred HIV prevention, care and treatment outpatient services at 62 health facilities in Western Kenya; 79,250 patients in care, of whom 27,046 are on HAART
- Retrospective cohort of HIV infected adults and children drawn from all 62 FACES clinical sites from across Nyanza province
- All HIV infected outpatients with positive serum Cryptococcal Antigen (sCrAg) tests identified from laboratory database between Jan 2006-Oct 2009
- Chart review of all positive sCrAg cases
- Exclusion: inpatient samples

Case Definitions:

- 1. Positive sCrAg
- 2. Positive sCrAg plus any symptom including headache
- 3. Positive sCrAg plus any other symptom excluding headache
- Lumbar puncture and cerebrospinal fluid (CSF) cultures not available in our care settings





Analysis

- Bivariate comparisons of key clinical characteristics between fatal and non-fatal CM cases was performed using Fishers exact test for proportions and t tests for continuous variables
- Logistic regression models used for multivariate analysis
- Sensitivity analysis to compare case fatality rates and relationships with key clinical predictors using 3 case definitions

Results

- 90 positive sCrAg tests identified from laboratory database
- 72(80%) of charts were found and reviewed
- Sensitivity analysis using more stringent clinical definitions of CM did not demonstrate significant difference in overall case fatality or bivariate relations (data not shown)
- No significant differences were observed between individuals with fatal and non fatal CM except for BMI
- No differences were observed between case fatality, current CD4 count, type of antifungal treatment, being on ARVs or any signs and symptoms of CM
- Higher BMI was significantly associated with lower case fatality in both multivariate and bivariate models

Table 1: Case fatality using different case definitions

Case Definitions for Cryptococcal Meningitis	N	Case fatality N (%)	Fishers exact P- value
1. Positive sCrAg	68	26 (38.2%)	
2. Positive sCrAg plus any symptom including headache	63	23 (36.5%)	0.96
3. Positive sCrAg plus any other symptom excluding headache	43	17 (39.5%)	

Table 2: Descriptive statistics and comparison of key clinical characteristics between fatal and non fatal CM cases using Definition 1

Characteristics	Overall (n=68)	Fatal CM cases (n=26)	Non-fatal CM cases (n=42)	P value
Age [mean (SD)]	38.3(9.2)	35.6 (8.3)	39.9 (9.4)	0.06
Female [n (%)]	33(48.5%)	13 (50.0)	20 (47.6)	1.00
CD4 Count [mean (SD)]	66.5(79.4)	49.2 (42.1)	76.4 (93.3)	0.06
CD4 Count median	39.5			
CD4 Count range	1-392			
BMI [mean (SD)]	18.7(4.06)	16.6 (2.8)	19.8 (4.2)	0.01
On ARVs for at least 2 wks prior to sCrAg [n (%)]	20(36.4%)	5 (35.7%)	15 (36.6)	1.00
Treatment type [n (%)] Fluconazole Amphotericin +/- Fluconazole	55(80.9%) 4(5.9%)	20(90.9%) 2 (9.1%)	35(94.6%) 2 (5.4%)	0.62

Symptoms	Overall (n=68)	Fatal CM cases (n=26)	Non-fatal CM cases (n=42)	P value
Fever	10(17.2%)	4(19%)	6(16%)	0.12
Headache	58(89.2%)	20 (80%)	38(95%)	0.097
Altered mental Status	8(12.3%)	5(20%)	3 (8%)	0.243
Stiff Neck	18(27.7%)	8 (32%)	10(25%)	0.578
Photophobia	11(16.9%)	4(16%)	7(18%)	1.00
Seizures	7(10.8%)	3(12%)	4(10%)	1.00
Focal Neurological Deficit	6(9.2%)	1(4.0%)	5(12.5%)	0.39

Table 3 (a): Bivariate analysis of key clinical predictors and case fatality using Definition 1

Clinical Predictors (continuous) Age in years CD4 Count BMI		Odds Ratio	P value
		0.95 1.00 0.75	0.06
			0.19
Gender	Female	39% (13/33)	1.00
	Male	37% (13/35)	
On ARVs for at least 2 wks prior to sCrAg	Yes	25% (5/20)	1.00
	No	26% (9/35)	
Treatment type [n (%)] Fluconazole		36% (20/55)	0.62

Table 3 (b): Bivariate analysis of key clinical predictors and case fatality using Definition 1

Symptoms	Case Fatality % (# dead/total)	P value
Fever	40% (4/10)	0.12
Headache	34% (20/58)	0.097
Altered mental Status	63% (5/8)	0.243
Stiff Neck	44% (8/18)	0.578
Photophobia	36% (4/11)	1.00
Seizures	43% (3/7)	1.00
Focal Neurological Deficit	17% (1/6)	0.39

Table 4: Multivariate logistic regression model of key clinical predictors and case fatality

Covariate	OR	95% CI	P VALUE
ВМІ	0.78	0.61,0.99	0.04
Current CD4 count	1.00	0.99,1.01	0.87
On ARVs for at least 2 wks prior to sCrAg	1.11	0.28,4.39	0.88

Limitations

- Small sample size
- Cryptococcal meningitis diagnosis based on sCrAg, not culture proven
- Missing charts

Conclusions

- CM has high case fatality rate of 38% in this out-patient cohort
- Higher BMI was associated with lower case fatality
- CD4 count was not a predictor of case fatality
- Type of anti fungal treatment was not associated with lower case fatality
- French, N., et al., Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS, 2002. 16(7): p. 1031-8. 11953469
 Lawn, S., et al., Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS, 2008. 22(15): p. 1897-1908.
- 3. Mwaba, P., et al., Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J, 2001. 77(914): p. 769-73. 11723315.
- 4. Bicanic, T., et al., Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV! Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. CLIN INFECT DIS, 2009. 49(5): p. 702-
- 709.

 5. van der Horst, C.M., et al., Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J





